Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 345.00p 330.00p 360.00p 345.00p 345.00p 345.00p 12,664 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 19.6 233

Eco Animal Health Share Discussion Threads

Showing 151 to 175 of 1075 messages
Chat Pages: Latest  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
29/7/2010
19:57
Lets hope so! That aside, I think there is plenty of potential upside just based on the value that Aivlosin can bring EAH with US approval in place and full realisation of sales potential across multiple regions. I'm not sure how much of a premium they can charge on the price of Aivlosin in the different markets, but with the opportunity for cheaper manufacture the company must only be 2-3 years away from significant profitability. This will mean they will be a cash rich company and thus very likely to be bought out.
audigger
29/7/2010
10:12
£4 getting nearer smell
smelleroo
29/7/2010
10:11
>AUdigger.You will soon be in serious profit.I am convinced that EAH will be bid for at several times todays sp!!
ltinvestor
26/7/2010
10:07
No stock available only 5k on offer.The so called big boys are on board and the company will probably be a bid target once US approval is confirmed.My guess for a takeout price of at least £4 possibly more if there is a bidding war.
ltinvestor
26/7/2010
09:50
I would love to buy at these prices, but ain't got spare cash at the moment. I last bought in April/May at 1.40 and thinking they wouldn't get much cheaper. Although I'm nursing a large paper loss there's no way I'd consider selling whilst the fundamentals remain sound. I wonder if the walk down in price is also to allow some of the big boys to get on board before it takes off?
audigger
26/7/2010
08:57
Aivlosin approval by FDA now a formality and should be received within a few months.I have been able to buy stock at 115 over the last couple of weeks and will try to buy more today.The mm's are short of stock and so are trying to frighten a few pi's into selling by lowering the sp!!Anybody who sells today shouldn't be investing in the market.
ltinvestor
26/7/2010
08:45
Good certainly do with something to inject some upward momentum in the SP!
audigger
26/7/2010
07:42
Good news this morning ahead of the results in a few weeks time.
topvest
02/6/2010
09:06
I believe back end of Autumn .That would be the day to buy even if mm's mark it up initially by 20p cos it will be much higher two weeks later.
ltinvestor
02/6/2010
07:32
I hope so. I wasn't sure about the timing of the FDA approval. Was the end of this year mentioned somewhere?
audigger
01/6/2010
09:32
I would think well northwards of £2.00 with FDA approval which is expected towards back end of this year.I am considering adding myself in the next couple of months.
ltinvestor
28/5/2010
15:52
All quiet on the EAH front. Added a few more today to average down having previously bought @1.98 & 1.65. Hopefully there will be a quick return to around 2.00 on news of FDA approval.
audigger
19/3/2010
15:34
A healthy turn-around. Long may it continue!
audigger
17/3/2010
20:41
yes Au plus eco already have a factory in china so may be there will be cost synergies from this JV smell
smelleroo
17/3/2010
20:25
Agree. They wouldn't embark on such a joint venture if they weren't confident the FDA approval was in the bag. It appears this deal gives them access to low cost manufacturing in China and the fact this facility is already FDA approved is one less hurdle.
audigger
17/3/2010
19:21
imho i think today's agreement implied something about that... smell
smelleroo
17/3/2010
07:28
All we need now is the FDA approval and away we go!
audigger
15/3/2010
21:11
up all of 1/2p today, but the recovery continues smell
smelleroo
12/3/2010
19:51
it seems to me that there was an overhang i.e. someone wanted to sell their stake and the eco share price had to be worked to a level to attract a buyer(s). 136p looks like the price at which this overhang cleared, this is going back up! would explain share price movement of late- going down on tiny volume. smell
smelleroo
12/3/2010
16:59
Looking like buys
audigger
12/3/2010
15:25
Interesting trades today.....buys or sells?
audigger
10/3/2010
20:13
http://www.proactiveinvestors.co.uk/companies/news/14233/eco-animal-health-group-moves-into-us-and-china-could-be-transformational-14233.html
ariane
10/3/2010
20:04
ariane, i see this is from proactive investors. who is the author Michael Sweeney? smell
smelleroo
10/3/2010
08:59
Eco Animal Health Group: moves into US and China could be transformational by Michael Sweeney ECO Animal Health Group (AIM: EAH) is a specialized veterinary drug company and a leader in the development, registration, and marketing of pharmaceutical products for global animal health markets. With a careful and responsible application of science, ECO delivers products to promote animal well-being and sustainable productivity. ECO's proprietary patented drug is Aivlosin®, which is a macrolide antibiotic for the treatment of respiratory and enteric diseases in pigs and poultry. Aivlosin targets a wide range of diseases that span from enzootic pneumonia to swine dysentery. The drug has been approved for use in pigs and poultry in Europe, South Africa, Japan, Asia, and South America. ECO expects to receive approvals this year for use in pigs in the United States. The Company now holds over 600 marketing authorizations in over 50 countries, and has developed strong relationships with distribution partners globally. With 100 employees located in five offices around the world and £19.3 million in revenues for FY 2009, the Company's products are recognized as offering security to both distributors and end users. Investment Thesis Aivlosin® now accounts for more than half of global sales for ECO. Sales in China during FY 2009 were more than 60% ahead of the previous year, and expectations for FY 2010 indicate similar progress. China is the largest market opportunity for ECO products in which it has a joint venture for sales and marketing ("ECO-BIOK"), and ECO is currently examining other joint in China. The Company is working on launch and distribution plans for the U.S. market, expecting to receive first marketing authorizations for Aivlosin from the Food and Drug Administration (FDA) in 2010. ECO is forecast by Cenkos Securities to increase its revenues to £22.4m in the FY March 31, 2010 and to £28.5m in 2011. EBITDA plus share-based payments and exceptional items are estimated at £3.6m and £5.3m respectively, which should translate to earnings per share of 4.7 pence and 7.4 pence. Cenkos expects ECO to produce step increases in earnings as new marketing authorizations are granted and new products are launched. Additionally it expects ECO's capital expenditure to fall substantially as the product registration program nears completion, resulting in increased cash flow. ECO's first half revenue from 4/1/09 to 9/30/09 rose 11% year to £8.9 million, while EBITDA jumped 32% to £1.94 million. The group had net cash of £3.2 at the end of the period. The increase in revenues was largely due to stronger sales of Aivlosin, which rose 10% after further marketing authorizations were secured in Europe. ECO has offered an upbeat outlook for the rest of FY 2010 (FYE is 3/31/10), as they expect business performance to improve further and projecting that Ecomectrin sales would pick up in the second half of the year. In 2009, EBITDA plus share-based payments and exceptional items increased 66.9% to £3.74 million (2008: £2.24 million). ECO paid a total dividend of 7.15 pence per share in 2008 and 2009, and it generated £3 million in cash from operating activities during 2009. ECO's Core Products Aivlosin® is ECO's proprietary patented macrolide drug, and it contains the innovative antibiotic Tylvalosin, The inclusion of Tylvalosin allows the drug to rapidly be absorbed and concentrated in target tissues to provide proven control of major respiratory and enteric diseases in both pigs and poultry. It is highly effective against a range of economically substantial diseases in pigs and poultry including: • Enzootic Pneumonia • Ileitis/PPE • Swine Dysentery • Mycoplasmosis • ORT • Necrotic Enteritis ECO continues to explore other potential uses of Aivlosin in production animals beyond pigs and poultry, such as cattle and horses. In June 2008, ECO was granted a marketing authorization from the European Commission for Aivlosin® granules for oral solution for poultry. It is the rapid absorption of Aivlosin® which results in a swift resolution of the disease and a fast return to productive health that makes it profitable for farmers to use when compared with older generation treatments. This authorization allows Aivlosin® to be marketed in Europe for the treatment and prevention of mycoplasmal respiratory disease in poultry, a segment estimated to be worth over £10 million per annum at the manufacturer level. In March 2009, ECO announced that it had received a positive opinion from the Committee for Medicinal Products for Veterinary Use of the European Medicines Agency for the use of Aivlosin® granules for oral solution for medicated drinking water for pigs. The Aivlosin® granules dissolve readily in drinking water thus enabling the rapid, accurate and simultaneous treatment of large numbers of pigs that are more likely to drink than to eat. This will allow Aivlosin® to be marketed throughout Europe for the treatment and prevention of ileitis. It is estimated that this market segment is worth £18 million per annum at manufacturer level. Generic Drugs - ECO is also making progress in its development of a new range of generic medications for pets, adding to its existing Ecoheart dog heartworm tablet and Ecomectin horse paste products. ECO has a number of generic drugs including Ecotraz and Ecomintic (endectocides & other antiparasitics) for the treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs. For the treatment of bacterial infections in pigs, poultry & cattle, ECO owns and distributes Chlortet and Oxytet. ECO has been granted a marketing authorization in Mexico for Ecoheart Chewable Tablets for dogs. Ecoheart tablets prevent heartworm disease and are also effective in the treatment and control of roundworms and hookworms in dogs. Canine heartworm infection is transmitted by mosquitoes. It is potentially fatal and requires a monthly preventative treatment. Ecoheart Chewable Tablets is the first companion animal product for which ECO has received a marketing authorization in Latin America where the pet sector is an important and growing market. Further marketing authorizations in the key markets of the region are expected. Research - ECO plans to build on the collaborative research deal it signed in 2006 with the University of Cambridge to investigate new potential indications for Aivlosin. Studies already completed have indicated that Aivlosin appears to prevent the replication of certain common viruses, including influenza, in laboratory test systems, without damaging cell cultures. Researchers at the Virology Division of the university's Department of Pathology have been awarded a £500,000 grant by the UK Medical Research Council to extend their work investigating inhibition of influenza viruses, and ECO's management believes that this work could have far reaching and exciting commercial applications for the firm. Prospects for the Future In a very difficult economy, ECO has performed very well. Now with markets in China opening and the U.S. expected this year, ECO has the potential to make even more progress. This should be a real launching pad for the Company. While there is a risk for ECO in the amount of revenues coming from one product, it does appear to have a loyal and growing following around the world.
ariane
09/3/2010
22:03
illiquid stock, fallen or very small volume fundamentals firmly intact smell
smelleroo
Chat Pages: Latest  7  6  5  4  3  2  1
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191015 01:06:16